{"id":{"repo_id":"uiuc","oai_identifier":"oai:www.ideals.illinois.edu:2142/44475"},"canonical_url":"https://search.dev.ndltd.org/etd/uiuc/oai:www.ideals.illinois.edu:2142/44475","repository":{"repo_id":"uiuc","name":"University of Illinois - Urbana-Champaign","base_url":"https://www.ideals.illinois.edu/oai-pmh"},"display":{"title":"Chemical and chemoenzymatic syntheses of lantibiotics and other bioactive cyclic peptides","abstract":"New antibiotics are desperately needed to combat the disturbing rise of pathogenic microorganisms resistant to traditional treatments. Throughout the history of modern medicine, natural products have played a leading role as a source and inspiration of new drugs, particularly antibacterial agents. One emerging family of natural products, the lanthipeptides, is defined by the presence of the thioether-containing crosslinks lanthionine and methyllanthionine and includes many members with promising activities against clinically-relevant bacterial pathogens, including drug-resistant strains. These peptides are biosynthesized by translation of a linear precursor peptide on the ribosome, followed by extensive post-translational modification that imparts substantial structural and functional diversity. In order to improve the pharmacological properties of lanthipeptides and therefore foster their clinical application, a more detailed understanding of their biological activities is essential. In this thesis, complementary synthetic platforms have been developed to produce lanthipeptides and analogues, and subsequent biological evaluation has revealed important information about the underpinnings of antibacteria activity in several compounds. In a chemoenzymatic approach described in Chapter II, the activity of an engineered biosynthetic enzyme involved in lacticin 481 maturation was reconstituted in vitro and used to produce a panel of lacticin 481 analogues from synthetic precursor peptides, several of which possessed improved antibacterial potency. This enhanced potency was correlated with improved inhibition of transglycosylation during peptidoglycan biosynthesis. Chapter III describes a chemical approach to lanthipeptide production; solid-phase peptide synthesis was utilized to generate the first reported analogues of the potent lanthipeptide epilancin 15X. These efforts provided the first details into structure-activity relationship analysis of this compound and also established it as a pore-forming agent. The total synthesis of lacticin 481 and analogues containing different crosslink stereochemical configurations was also accomplished, which revealed that the natural crosslink configurations are required for biological activity. In Chapter IV, this solid-supported chemical approach was applied to the generation of potent analogues of the immunomodulatory peptide compstatin via substitution of the reduction-labile disulfide moiety for an isosteric thioether that is stable to reduction. The generality of these synthetic platforms allows for similar engineering approaches in other lanthipeptides and other classes of bioactive cyclic peptides, in order to improve the therapeutic potential of these intriguing compounds.","abstract_html":"New antibiotics are desperately needed to combat the disturbing rise of pathogenic microorganisms resistant to traditional treatments. Throughout the history of modern medicine, natural products have played a leading role as a source and inspiration of new drugs, particularly antibacterial agents. One emerging family of natural products, the lanthipeptides, is defined by the presence of the thioether-containing crosslinks lanthionine and methyllanthionine and includes many members with promising activities against clinically-relevant bacterial pathogens, including drug-resistant strains. These peptides are biosynthesized by translation of a linear precursor peptide on the ribosome, followed by extensive post-translational modification that imparts substantial structural and functional diversity. In order to improve the pharmacological properties of lanthipeptides and therefore foster their clinical application, a more detailed understanding of their biological activities is essential. In this thesis, complementary synthetic platforms have been developed to produce lanthipeptides and analogues, and subsequent biological evaluation has revealed important information about the underpinnings of antibacteria activity in several compounds. In a chemoenzymatic approach described in Chapter II, the activity of an engineered biosynthetic enzyme involved in lacticin 481 maturation was reconstituted in vitro and used to produce a panel of lacticin 481 analogues from synthetic precursor peptides, several of which possessed improved antibacterial potency. This enhanced potency was correlated with improved inhibition of transglycosylation during peptidoglycan biosynthesis. Chapter III describes a chemical approach to lanthipeptide production; solid-phase peptide synthesis was utilized to generate the first reported analogues of the potent lanthipeptide epilancin 15X. These efforts provided the first details into structure-activity relationship analysis of this compound and also established it as a pore-forming agent. The total synthesis of lacticin 481 and analogues containing different crosslink stereochemical configurations was also accomplished, which revealed that the natural crosslink configurations are required for biological activity. In Chapter IV, this solid-supported chemical approach was applied to the generation of potent analogues of the immunomodulatory peptide compstatin via substitution of the reduction-labile disulfide moiety for an isosteric thioether that is stable to reduction. The generality of these synthetic platforms allows for similar engineering approaches in other lanthipeptides and other classes of bioactive cyclic peptides, in order to improve the therapeutic potential of these intriguing compounds.","abstract_has_math":false,"creators":["Knerr, Patrick"],"institution":"University of Illinois at Urbana-Champaign","degree_name":"Ph.D.","degree_level":"Dissertation","degree_discipline":"Chemistry","degree_department":null,"school":null,"contributors":["van der Donk, Wilfred A.","Hergenrother, Paul J.","Katzenellenbogen, John A.","Nair, Satish K."],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2013,"date_issued":"2013-05-24T22:17:29Z","date_published":"2013-05-24T22:17:29Z","updated_at":"2026-07-22T22:25:34Z","subjects":["Lantibiotics","Lanthipeptides","natural products","epilancin 15X","lacticin 481","LctM","compstatin","ribosomally synthesized and post-translationally modified peptides","RiPPs","post-translational modification","cyclic peptides","antibiotics","peptide synthesis","solid-phase peptide synthesis (SPPS)","biosynthetic engineering","thioether","structure-activity relationship","disulfide engineering"],"languages":["en"],"rights":["Copyright 2013 Patrick James Knerr"],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/2142/44475","outbound_label":"Handle","outbound_source":"dc:identifier"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["van der Donk, Wilfred A.","Hergenrother, Paul J.","Katzenellenbogen, John A.","Nair, Satish K."]},{"key":"dc:creator","label":"Author","values":["Knerr, Patrick"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2013-05-24T22:17:29Z","2015-05-24T10:01:23Z","2013-05"]},{"key":"dc:type","label":"Dc Type","values":["text"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Ph.D."]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["University of Illinois at Urbana-Champaign"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Lantibiotics","Lanthipeptides","natural products","epilancin 15X","lacticin 481","LctM","compstatin","ribosomally synthesized and post-translationally modified peptides","RiPPs","post-translational modification","cyclic peptides","antibiotics","peptide synthesis","solid-phase peptide synthesis (SPPS)","biosynthetic engineering","thioether","structure-activity relationship","disulfide engineering"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Copyright 2013 Patrick James Knerr"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["http://hdl.handle.net/2142/44475"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description","label":"Description","values":["New antibiotics are desperately needed to combat the disturbing rise of pathogenic microorganisms resistant to traditional treatments. Throughout the history of modern medicine, natural products have played a leading role as a source and inspiration of new drugs, particularly antibacterial agents. One emerging family of natural products, the lanthipeptides, is defined by the presence of the thioether-containing crosslinks lanthionine and methyllanthionine and includes many members with promising activities against clinically-relevant bacterial pathogens, including drug-resistant strains. These peptides are biosynthesized by translation of a linear precursor peptide on the ribosome, followed by extensive post-translational modification that imparts substantial structural and functional diversity. In order to improve the pharmacological properties of lanthipeptides and therefore foster their clinical application, a more detailed understanding of their biological activities is essential. In this thesis, complementary synthetic platforms have been developed to produce lanthipeptides and analogues, and subsequent biological evaluation has revealed important information about the underpinnings of antibacteria activity in several compounds. In a chemoenzymatic approach described in Chapter II, the activity of an engineered biosynthetic enzyme involved in lacticin 481 maturation was reconstituted in vitro and used to produce a panel of lacticin 481 analogues from synthetic precursor peptides, several of which possessed improved antibacterial potency. This enhanced potency was correlated with improved inhibition of transglycosylation during peptidoglycan biosynthesis. Chapter III describes a chemical approach to lanthipeptide production; solid-phase peptide synthesis was utilized to generate the first reported analogues of the potent lanthipeptide epilancin 15X. These efforts provided the first details into structure-activity relationship analysis of this compound and also established it as a pore-forming agent. The total synthesis of lacticin 481 and analogues containing different crosslink stereochemical configurations was also accomplished, which revealed that the natural crosslink configurations are required for biological activity. In Chapter IV, this solid-supported chemical approach was applied to the generation of potent analogues of the immunomodulatory peptide compstatin via substitution of the reduction-labile disulfide moiety for an isosteric thioether that is stable to reduction. The generality of these synthetic platforms allows for similar engineering approaches in other lanthipeptides and other classes of bioactive cyclic peptides, in order to improve the therapeutic potential of these intriguing compounds.","Item withdrawn by Mark Zulauf (zulauf@illinois.edu) on 2013-04-10T19:04:20Z Item was in collections: University of Illinois Theses & Dissertations (ID: 1) No. of bitstreams: 1 Knerr_Patrick.pdf: 9687251 bytes, checksum: 2a92154a9d80bcc2dade56c319bc81cc (MD5)","Made available in DSpace on 2013-05-24T22:17:29Z (GMT). No. of bitstreams: 2 Patrick_Knerr.pdf: 9675248 bytes, checksum: 7873341a869f29e3bd3b0ae6b950f4c2 (MD5) license.txt: 4061 bytes, checksum: 245c9cf8244070b4437274f070ad68b0 (MD5)","Restriction data tranferred 2014-07-01T11:36:17-05:00 Original Data Group with Access UIUC Users [automated] Release Date: 2015-05-24 17:18:31 UTC Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Item marked as restricted to the 'UIUC Users [automated]' Group (id=2) by Seth Robbins (srobbins@illinois.edu) on 2013-05-24T22:19:17Z Item is restricted until 2015-05-24T22:18:31Z","U of I Only Restriction Lifted for Item 44448 on 2015-05-24T10:01:23Z."]},{"key":"dc:title","label":"Title","values":["Chemical and chemoenzymatic syntheses of lantibiotics and other bioactive cyclic peptides"]}]}],"canonical_facts":{"dc:contributor":["van der Donk, Wilfred A.","Hergenrother, Paul J.","Katzenellenbogen, John A.","Nair, Satish K."],"dc:creator":["Knerr, Patrick"],"dc:date":["2013-05-24T22:17:29Z","2015-05-24T10:01:23Z","2013-05"],"dc:description":["New antibiotics are desperately needed to combat the disturbing rise of pathogenic microorganisms resistant to traditional treatments. Throughout the history of modern medicine, natural products have played a leading role as a source and inspiration of new drugs, particularly antibacterial agents. One emerging family of natural products, the lanthipeptides, is defined by the presence of the thioether-containing crosslinks lanthionine and methyllanthionine and includes many members with promising activities against clinically-relevant bacterial pathogens, including drug-resistant strains. These peptides are biosynthesized by translation of a linear precursor peptide on the ribosome, followed by extensive post-translational modification that imparts substantial structural and functional diversity. In order to improve the pharmacological properties of lanthipeptides and therefore foster their clinical application, a more detailed understanding of their biological activities is essential. In this thesis, complementary synthetic platforms have been developed to produce lanthipeptides and analogues, and subsequent biological evaluation has revealed important information about the underpinnings of antibacteria activity in several compounds. In a chemoenzymatic approach described in Chapter II, the activity of an engineered biosynthetic enzyme involved in lacticin 481 maturation was reconstituted in vitro and used to produce a panel of lacticin 481 analogues from synthetic precursor peptides, several of which possessed improved antibacterial potency. This enhanced potency was correlated with improved inhibition of transglycosylation during peptidoglycan biosynthesis. Chapter III describes a chemical approach to lanthipeptide production; solid-phase peptide synthesis was utilized to generate the first reported analogues of the potent lanthipeptide epilancin 15X. These efforts provided the first details into structure-activity relationship analysis of this compound and also established it as a pore-forming agent. The total synthesis of lacticin 481 and analogues containing different crosslink stereochemical configurations was also accomplished, which revealed that the natural crosslink configurations are required for biological activity. In Chapter IV, this solid-supported chemical approach was applied to the generation of potent analogues of the immunomodulatory peptide compstatin via substitution of the reduction-labile disulfide moiety for an isosteric thioether that is stable to reduction. The generality of these synthetic platforms allows for similar engineering approaches in other lanthipeptides and other classes of bioactive cyclic peptides, in order to improve the therapeutic potential of these intriguing compounds.","Item withdrawn by Mark Zulauf (zulauf@illinois.edu) on 2013-04-10T19:04:20Z Item was in collections: University of Illinois Theses & Dissertations (ID: 1) No. of bitstreams: 1 Knerr_Patrick.pdf: 9687251 bytes, checksum: 2a92154a9d80bcc2dade56c319bc81cc (MD5)","Made available in DSpace on 2013-05-24T22:17:29Z (GMT). No. of bitstreams: 2 Patrick_Knerr.pdf: 9675248 bytes, checksum: 7873341a869f29e3bd3b0ae6b950f4c2 (MD5) license.txt: 4061 bytes, checksum: 245c9cf8244070b4437274f070ad68b0 (MD5)","Restriction data tranferred 2014-07-01T11:36:17-05:00 Original Data Group with Access UIUC Users [automated] Release Date: 2015-05-24 17:18:31 UTC Reason: Author requested U of Illinois access only (OA after 2yrs) in Vireo ETD system","Item marked as restricted to the 'UIUC Users [automated]' Group (id=2) by Seth Robbins (srobbins@illinois.edu) on 2013-05-24T22:19:17Z Item is restricted until 2015-05-24T22:18:31Z","U of I Only Restriction Lifted for Item 44448 on 2015-05-24T10:01:23Z."],"dc:identifier":["http://hdl.handle.net/2142/44475"],"dc:language":["en"],"dc:rights":["Copyright 2013 Patrick James Knerr"],"dc:subject":["Lantibiotics","Lanthipeptides","natural products","epilancin 15X","lacticin 481","LctM","compstatin","ribosomally synthesized and post-translationally modified peptides","RiPPs","post-translational modification","cyclic peptides","antibiotics","peptide synthesis","solid-phase peptide synthesis (SPPS)","biosynthetic engineering","thioether","structure-activity relationship","disulfide engineering"],"dc:title":["Chemical and chemoenzymatic syntheses of lantibiotics and other bioactive cyclic peptides"],"dc:type":["text"],"thesis:degree_discipline":["Chemistry"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Ph.D."],"thesis:institution_name":["University of Illinois at Urbana-Champaign"]},"updated_at":"2026-07-22T22:25:34Z"}